Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 16/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258630 | 0.89 | CYP1A2 (0.46) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL24444132 | 0.89 | CYP1A2 (0.46) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL21264012 | 0.83 | SLC29A1 (0.46) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL24258589 | 0.83 | SLC29A1 (0.39) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL21263864 | 0.83 | SLC29A1 (0.56) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL25688724 | 0.79 | SLC29A1 (0.49) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL25688725 | 0.74 | SLC29A1 (0.39) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL21263857 | 0.71 | LMNA (0.41) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL24322068 | 0.70 | SLC29A1 (0.32) | SLC29A1 | |
| SCHEMBL20908785 | 0.70 | CYP1A2 (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |